IN THE UNITED STATES PATENT & TRADEMARK OFFICE

re application of	)
SANJAY M. REDDY et al.	)
Marek'S Disease Virus Vaccine	)
Serial No. 10/623,891	)
Filed July 21, 2003	)

The Honorable

The Assistant Commissioner for Patents
Sir:

## Information Disclosure Statement

Pursuant to 37 C.F.R. 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

- I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>
  The patents, publications or other information submitted for consideration by the Office (except U.S. patent applications) are listed on PTO/SB/08a/b, attached hereto.
- II. <u>COPIES</u> (check at least one item)
  - a. X Submitted herewith is a legible copy of (I) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all

Postal Servi	fy that this correspondence is being deposited with the U e as First Class Mail in an envelope addressed to: r for Patents, P.O. Box 1450, Alexandria, VA 22313-145	
	August 27, 2003	
	(Date of Deposit)	
	Randall E. Deck	
	Name of Depositor	
	Signature	
	8/27/03	
	/ Date of Signature	

other information or that portion which caused it to be listed, except that no copy of a U.S. patent application is included.

b. \_\_\_ Any patents, publications or other information which are listed on PTO/SB/08a/b or on the copies of PTO 892 but which are not enclosed herewith were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. 120:

## U.S. Serial Number

U.S. Filing Date

- III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one item)
  - a. X Except as may be indicated below in (b), all of the patents, publications or other information are in the English language (concise explanation not required).
  - b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
  - c.\_\_\_ The following additional information is provided for the Examiner's consideration:
- IV. CROSS REFERENCE TO RELATED APPLICATIONS

  The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this (these) application(s) to the Examiner's attention, applicant does not waive the confidentiality provisions of 35 U.S.C. 122:

## **FEES**

- V. X THIS IDS IS BEING FILED UNDER 37 C.F.R. 1.97(b): (check one item)
  - a. X Within three months of the filing date of a national application [37 C.F.R. 1.97(b)(1)]. No fee or certification is required.
  - b. \_\_\_ Within three months of the date of entry of the national stage as set forth in 1.491 in an international application [37 C.F.R. 1.97(b)(2)]. No fee or certification is required.

merits [37 C.F.R 1.97(b)(3)]. No fee or certification is required. VI. \_\_\_\_ THIS IDS IS BEING FILED UNDER 37 C.F.R. 1.97(c): before the mailing date of a Final Office Action under 37 C.F.R. 1.113 [See 37 C.F.R. 1.97(c)(1)] or before the mailing date of a Notice of Allowance under 37 C.F.R. 1.311 [See 37 C.F.R. 1.97(c)(2)]. (check one item) a. \_\_\_ No certification; therefore, a fee in the amount of \$\_\_\_\_\_ is required by 37 C.F.R. 1.17(p); or b.\_\_\_ See the certification below. No fee is required. VII. Certification Under 37 C.F.R. 1.97(e) The undersigned hereby certifies that: (check <u>only</u> one item) a.\_\_\_ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or b.\_\_\_ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(C) more than three months prior to the filing of this statement. c.\_\_\_ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign

c.\_\_\_ Before the mailing date of a first Action on the

making reasonable inquiry, was known to any

application or, to the best of my knowledge after

individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

## VIII. Payment of Fees (check one item)

- a. X NO FEE IS REQUIRED.
- b. Please charge Deposit Account No. 50-2132 in the amount of \$\_\_\_\_\_ for the above-indicated fee.

This Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; or (iii) the cited information constitutes prior art in the subject application.

If this IDS is determined to not fully comply with the rules, the Examiner is urged to contact the undersigned.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. 1.16 or 1.17 to Deposit Account 50-2132.

Respectfully submitted,

Peoria, IL

Randall E. Deck, Agent of Record Registration No. 34,078

(309) 681-6515

FAX: (309) 681-6688

(202) 720-2421

Enclosures:

X PTO/SB/08a/b

\_\_\_\_ PTO-892

X References (5)

\_\_\_ Foreign Search Report

Fee

\_\_\_ Other:

PTO/SB/08b (08-03) Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. Defarmation unless it contains a valid OMB control under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

and a separation recognists of 1999, the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs it contains a valid of the persons are required to respond to a confection of information differs in the persons are required to respond to a confection of the persons are required to the person are require						
Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			OCUDE	Application Number	10/623,891	
				Filing Date	July 21, 2003	
			LICANT	First Named Inventor	Sanjay M. Reddy	
			cessary)	Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number	0167.03	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AR1	R. L. WITTER et al., Retroviral Insertional Mutagenesis of a Herpesvirus: A Marek's Disease Virus Mutant Attenuated for Oncogenicity but not for Immunosuppression or In Vivo Replication, Avian Diseases 41:407-421, 1997	
	AS1	DAN JONES et al., Retroviral Insertional Activation in a Herpesvirus: Transcriptional Activation of U <sub>s</sub> Genes by an Integrated Long Terminal Repeat in a Marek's Disease Virus Clone, Journal of Virology, April 1996, pp. 2460-2467	
	AT1	DAN JONES et al., Retroviral Insertions into a Herpesvirus are Clustered at the Junctions of the Short Repeat and Short Unique Sequences, Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 3855-3859, May 1993	
	AU1	RHONDA KOST et al., Retrovirus Insertion into Herpesvirus: Characterization of a Marek's Disease Virus Harboring a Solo LTR, Virology 192, 161-169, 1993	
	AV1	ROBERT ISFORT et al., Retrovirus Insertion into Herpesvirus in Vitro and in Vivo, Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 991-995, February 1992	
			_
			_
			_
			_
			_

Examiner	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.